» Articles » PMID: 21360758

The Majority of Infiltrating CD8 T Lymphocytes in Multiple Sclerosis Lesions is Insensitive to Enhanced PD-L1 Levels on CNS Cells

Overview
Journal Glia
Specialty Neurology
Date 2011 Mar 2
PMID 21360758
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Central nervous system (CNS) cells locally modulate immune responses using numerous molecules that are not fully elucidated. Engagement of programmed death-1 (PD-1), expressed on activated T cells, by its ligands (PD-L1 or PD-L2) suppresses T-cell responses. Enhanced CNS PD-1 and PD-L1 expression has been documented in inflammatory murine models; however, human CNS data are still incomplete. We determined that human primary cultures of astrocytes, microglia, oligodendrocytes, or neurons expressed low or undetectable PD-L1 under basal conditions, but inflammatory cytokines significantly induced such expression, especially on astrocytes and microglia. Blocking PD-L1 expression in astrocytes using specific siRNA led to significantly increased CD8 T-cell responses (proliferation, cytokines, lytic enzyme). Thus, our results establish that inflamed human glial cells can express sufficient and functional PD-L1 to inhibit CD8 T cell responses. Extensive immunohistochemical analysis of postmortem brain tissues demonstrated a significantly greater PD-L1 expression in multiple sclerosis (MS) lesions compared with control tissues, which colocalized with astrocyte or microglia/macrophage cell markers. However, more than half of infiltrating CD8 T lymphocytes in MS lesions did not express PD-1, the cognate receptor. Thus, our results demonstrate that inflamed human CNS cells such as in MS lesions express significantly elevated PD-L1, providing a means to reduce CD8 T cell responses, but most of these infiltrating immune cells are devoid of PD-1 and thus insensitive to PD-L1/L2. Strategies aimed at inducing PD-1 on deleterious activated human CD8 T cells that are devoid of this receptor could provide therapeutic benefits since PD-L1 is already increased in the target organ.

Citing Articles

Therapeutic Targeting of Glioblastoma and the Interactions with Its Microenvironment.

Genoud V, Kinnersley B, Brown N, Ottaviani D, Mulholland P Cancers (Basel). 2023; 15(24).

PMID: 38136335 PMC: 10741850. DOI: 10.3390/cancers15245790.


Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.

Daei Sorkhabi A, Komijani E, Sarkesh A, Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L Cell Commun Signal. 2023; 21(1):321.

PMID: 37946301 PMC: 10634124. DOI: 10.1186/s12964-023-01289-9.


Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1.

Smith B, Tinkey R, Brock O, Mariam A, Habean M, Dutta R J Neuroinflammation. 2023; 20(1):234.

PMID: 37828609 PMC: 10568873. DOI: 10.1186/s12974-023-02917-4.


PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation.

Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, Losslein L, Vandrey O Nat Commun. 2023; 14(1):5555.

PMID: 37689786 PMC: 10492803. DOI: 10.1038/s41467-023-40982-8.


Women in the field of multiple sclerosis: How they contributed to paradigm shifts.

Barateiro A, Barros C, Pinto M, Ribeiro A, Alberro A, Fernandes A Front Mol Neurosci. 2023; 16:1087745.

PMID: 36818652 PMC: 9937661. DOI: 10.3389/fnmol.2023.1087745.


References
1.
Carter L, Fouser L, Jussif J, Fitz L, Deng B, Wood C . PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002; 32(3):634-43. DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9. View

2.
Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M . Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009; 183(8):4984-93. DOI: 10.4049/jimmunol.0901038. View

3.
Lafon M, Megret F, Meuth S, Simon O, Velandia Romero M, Lafage M . Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol. 2008; 180(11):7506-15. DOI: 10.4049/jimmunol.180.11.7506. View

4.
Ortler S, Leder C, Mittelbronn M, Zozulya A, Knolle P, Chen L . B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol. 2008; 38(6):1734-44. DOI: 10.1002/eji.200738071. View

5.
Saikali P, Antel J, Newcombe J, Chen Z, Freedman M, Blain M . NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci. 2007; 27(5):1220-8. PMC: 6673175. DOI: 10.1523/JNEUROSCI.4402-06.2007. View